Gulf International Bank UK Ltd lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 33.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,788 shares of the medical equipment provider's stock after selling 5,518 shares during the quarter. Gulf International Bank UK Ltd's holdings in Zimmer Biomet were worth $1,220,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of ZBH. JPMorgan Chase & Co. raised its stake in shares of Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after acquiring an additional 1,488,918 shares in the last quarter. Nuveen LLC bought a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $155,891,000. Nuveen Asset Management LLC raised its stake in shares of Zimmer Biomet by 191.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock worth $146,763,000 after acquiring an additional 913,310 shares in the last quarter. Freestone Grove Partners LP bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $67,954,000. Finally, Boston Trust Walden Corp bought a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $54,108,000. Institutional investors own 88.89% of the company's stock.
Zimmer Biomet Stock Performance
Shares of NYSE ZBH opened at $102.77 on Friday. The company's fifty day moving average price is $94.36 and its 200 day moving average price is $99.48. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $116.71. The company has a market capitalization of $20.36 billion, a PE ratio of 25.00, a price-to-earnings-growth ratio of 2.01 and a beta of 0.68. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the prior year, the firm posted $2.01 earnings per share. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.
Zimmer Biomet Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were given a dividend of $0.24 per share. The ex-dividend date was Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet's dividend payout ratio is currently 23.36%.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. JMP Securities cut their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. UBS Group set a $96.00 price target on shares of Zimmer Biomet and gave the company a "sell" rating in a research note on Friday, August 8th. Roth Capital restated a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Truist Financial set a $101.00 price target on shares of Zimmer Biomet in a research note on Tuesday, May 6th. Finally, Wells Fargo & Company cut their price target on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $111.44.
Read Our Latest Stock Analysis on Zimmer Biomet
Insiders Place Their Bets
In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.39% of the company's stock.
Zimmer Biomet Profile
(
Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.